Latest News

ADRI Scientists present at the 2014 iMig Conference

Researchers from ADRI were well represented at the recent International Mesothelioma Interest Group (iMig) Conference, which was held from 21-24 October in Cape Town. A large number of presentations were made, including 7 short talks and 5 posters, reflecting the broad spectrum of research carried out at ADRI. Find details…

Read More

ADRI Publishes new research

A study led by ADRI Researcher Dr Anthony Linton has recently appeared in the British Journal of Cancer. The article explores the clinical, pathological and treatment factors associated with prolonged survival in malignant pleural mesothelioma. In a large series of 910 patients registered with the NSW Dust Diseases Board, the…

Read More

Open Day for Honours and Phd Students

ADRI, together with its neighbour the ANZAC Research Institute, is actively seeking high calibre honours and PhD candidates who demonstrate initiative and innovative thought for Hounours and PhD projects focusing on cancer research.   Why choose Cancer Research at Concord Clinical School?   We host state of the art research…

Read More

MesomiR 1, A Phase I study of TargomiRs as 2nd or 3rd line treatment for patients with recurrent MPM and NSCLC

MesomiR 1, A Phase I study of TargomiRs as 2nd or 3rd line treatment for patients with recurrent MPM and NSCLC The ADRI, together with biotech company EnGeneIC, is running an early stage clinical trial of a new approach to therapy for selected patients with malignant pleural mesothelioma or non-small…

Read More

ADRI-led team wins award for rapid progress to clinical trial

The Cancer Institute NSW Premier’s Awards for Outstanding Cancer Research is an annual event that celebrates excellence and innovation in cancer research. Seven awards were presented on Friday, August 22, to those leading the way in their field. Dr Glen Reid, from the Asbestos Disease Research Institute, accepted one of the…

Read More

Mesothelioma Support Coordinator

Jocelyn McLean joins the Asbestos Diseases Research Institute (ADRI), after many years of caring for patients having surgery for lung cancer, mesothelioma and benign conditions at Royal Prince Alfred Hospital. Utilising her knowledge and experience of patient and carer needs and drawing from current survivorship research and carer need research…

Read More

Patient study: Quality of life

Quality of life in patients with Mesothelioma The ADRI is running a study investigating ‘quality of life’ in patients diagnosed with mesothelioma. While we are aware that there is a high symptom burden in patients suffering from mesothelioma, we have little information on ‘quality of life’ in people living with…

Read More

ADRI Research recognised by award at WIN Symposium

The research leading to ADRI’s upcoming clinical trial has been recognised by the award of one of two best poster prizes at the recent WIN Symposium 2014 in Paris. The study describes the translational research leading to the new microRNA-based treatment approach for malignant pleural mesothelioma and non-small cell lung…

Read More

New research results show deadly asbestos-related cancer slowed down

Australian scientists, inventors and surgeons worked together in ground-breaking research that has lead to the discovery of a way to slow down the growth of deadly asbestos-related cancer malignant pleural mesothelioma. The break-through underpins a clinical trial due to start in six weeks.

More than 10,000 Australians have died since the early 1980s, with more than 25,000 expected to die over the next four decades, because of mesothelioma, an asbestos-related cancer. The cancer can take up to 40 years to develop.

Read More

Prize for ADRI researcher

This year’s finals of the Concord Repatriation General Hospital Early Career Research Awards were held on 22nd and 29th of October at the ANZAC Research Institute. These yearly research prizes are co-sponsored by Concord Hospital and the ANZAC Research Institute and awarded to early career researchers who primarily undertake their work on…

Read More